Cargando…

The Multiple Sclerosis Treatment Optimization Program

OBJECTIVE: To design and implement a health system level intervention to reduce escalating multiple sclerosis (MS) disease modifying treatment (DMT) expenditures and improve outcomes. METHODS: We conducted stakeholder meetings, reviewed pharmacy utilization data, and abstracted information in subset...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langer‐Gould, Annette, Cheng, Stephen C., Li, Bonnie H., Kanter, Michael H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607446/ https://www.ncbi.nlm.nih.gov/pubmed/34662494 http://dx.doi.org/10.1002/acn3.51472

Ejemplares similares

Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level
por: Langer‐Gould, Annette, et al.
Publicado: (2022)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Racial and Ethnic Disparities in Multiple Sclerosis Prevalence
por: Langer-Gould, Annette M., et al.
Publicado: (2022)

Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
por: Smith, Jessica B., et al.
Publicado: (2022)

Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility
por: Hellwig, Kerstin, et al.
Publicado: (2016)

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
por: Alping, Peter, et al.
Publicado: (2019)

Improving quality, affordability, and equity of multiple sclerosis care
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2023)

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis
por: Langer-Gould, Annette, et al.
Publicado: (2018)

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022)

MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics
por: Langer-Gould, Annette, et al.
Publicado: (2018)

Optimizing treatment success in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Outcome measures assisting treatment optimization in multiple sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2021)

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
por: Fink, Katharina, et al.
Publicado: (2023)

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
por: Patti, Francesco
Publicado: (2010)

Optimizing multiple sclerosis diagnosis: gene expression and genomic association
por: Gurevich, Michael, et al.
Publicado: (2015)

Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region
por: Hittle, Michael, et al.
Publicado: (2023)

Multiple Sclerosis and Its Treatment
por: Giovannoni, Gavin, et al.
Publicado: (1999)

One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program
por: Groeneweg, Marti, et al.
Publicado: (2018)

Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations
por: Arnold, Douglas L, et al.
Publicado: (2015)

Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria
por: Ruiz-Peña, Juan Luís, et al.
Publicado: (2008)

The evaluation of an online mindfulness program for people with multiple sclerosis: study protocol
por: Sesel, Amy-Lee, et al.
Publicado: (2019)

Editorial Response to Drs. Simone and Mancusi
por: Langer-Gould, Annette
Publicado: (2020)

Treatment of Cognitive Impairment in Multiple Sclerosis
por: Pierson, Susan H., et al.
Publicado: (2006)

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
por: Kolb-Mäurer, Annette, et al.
Publicado: (2015)

Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021)

Specific hypomethylation programs underpin B cell activation in early multiple sclerosis
por: Ma, Qin, et al.
Publicado: (2021)

Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry
por: Chi, Calvin, et al.
Publicado: (2019)

Rehabilitation treatment of multiple sclerosis
por: Duan, Haoyang, et al.
Publicado: (2023)

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
por: Visser, Leo H, et al.
Publicado: (2016)

Treatment of multiple sclerosis
por: Pandit, Lekha, et al.
Publicado: (2011)

Viral etiology of multiple sclerosis: where does the truth lie?
por: Waksman, Byron H., et al.
Publicado: (1986)

Treatment of Multiple Sclerosis With Chinese Scalp Acupuncture
por: Hao, Jason Jishun, et al.
Publicado: (2013)

Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis
por: Ghadiri, Mahtab, et al.
Publicado: (2020)

Symptom changes in multiple sclerosis following psychological interventions: a systematic review
por: Pagnini, Francesco, et al.
Publicado: (2014)

Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosis
por: Piggott, Thomas, et al.
Publicado: (2021)

Long‐term evolution of multiple sclerosis disability in the treatment era
por: Cree, Bruce A. C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_evtbcdupi1akb9r8ah8im21oel